4.7 Article

Varenicline and P50 auditory gating in medicated schizophrenic patients: A pilot study

Journal

PSYCHIATRY RESEARCH
Volume 175, Issue 1-2, Pages 179-180

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2009.01.025

Keywords

Schizophrenia; Sensory gating; Varenicline

Categories

Funding

  1. [VISN19/MIRECC]
  2. [RO1 MH50787-08.]
  3. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050787] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Most schizophrenic patients have a deficit in auditory sensory gating that appears to be mediated by the alpha-7 nicotinic receptor. This pilot study examines the effects of varenicline, an alpha-7 agonist, on the P50 auditory evoked potential in six schizophrenic patients. The study was canceled because of concerning side effects consistent with those reported by the FDA. However, in this small group of subjects, varenicline did not consistently enhance P50 auditory gating. Published by Elsevier Ireland Ltd

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available